You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

400 Results
Symptom Management
Drug
Other Name(s): Inrebic®
Jul 2025
Document
New
Jul 2025
Drug
Other Name(s): Welireg®
Jul 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Aug 2025
Drug
Other Name(s): Faslodex®
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Aug 2025

Pages